Fagron N.V.

Transaction in Own Shares • Mar 2, 2015

Disclosure of acquisition of treasury shares

Fagron discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Fagron today announces that during the period from 23 February 2015 to 27 February 2015, it acquired 17,500 treasury shares on Euronext Brussels.

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
23 February 2015	5,000	€ 32.9544	€ 32.92	€ 32.97	€ 164,772
24 February 2015	6,500	€ 32.7854	€ 32.70	€ 32.85	€ 213,105
25 February 2015	1,000	€ 32.8600	€ 32.86	€ 32.86	€ 32,860
26 February 2015	3,000	€ 32.8129	€ 32.76	€ 32.86	€98,439
27 February 2015	2,000	€ 32.8100	€ 32.76	€ 32.86	€ 65,620

Prior to the transactions, Fagron held 613,979 treasury shares. As a result of the acquisition of 17,500 treasury shares, Fagron now holds 631,479 treasury shares, representing 2.01% of the total number of shares outstanding.

Fagron will publish a weekly update every Monday provided that shares were bought back in the preceding week.

1 This press release was sent out by Fagron NV and Fagron BV.

Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron offers Fagron Compounding Essentials, Fagron Trademarks and Fagron Compounding Services to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organisation consists of more than 300 pharmacists who are working continually on developing new formulations to treat an increasing number of patients with customised compounded medication.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra Global Investor Relations Director Tel. +31 88 33 11 213 marieke.palstra@fagron.com investors.fagron.com

In the event of any discrepancy between the Dutch translation and the original English version of this press release, the latter shall prevail.